Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma


Disclosures: SSN reports honoraria and research support from Kite, a Gilead Company, Merck, Celgene, research support from Bristol-Myers Sqibb, Poseida, Cellectis, Karus, and Acerta Pharma, and honoraria from Novartis, Pfizer, and Unum Therapeutics. FS reports honoraria from Celgene. LJN reports honoraria from Celgene, Genentech, Gilead, Janssen, Juno, Novartis, Spectrum, TG Therapeutics and research support from Celgene, Genentech, Janssen, Karus Therapeutics, and Merck. NHF reports honoraria from Celgene, Gilead Sciences, Pharmacyclics, Roche Pharma AG, research support from Celgene, Gilead Sciences, Pharmacyclics, and Roche Pharma AG.

Contributions: PS designed the study, analyzed data, and wrote the paper; NF, LJN, FS, LEF, FBH, JER, AR, MW, JRW, RED provided clinical care to patients and coauthored the paper; MAA, CC, and MN collected clinical data, reviewed PET reports, and coauthored the paper; LF provided statistical support and coauthored the paper; SN designed the study, analyzed the data, provided clinical care to patients, and wrote the paper.